Related Experiment Videos
Evaluating progress toward Healthy People 2010 national diabetes objectives
Qaiser Mukhtar1, Leonard Jack, Maurice Martin
1Applied Behavioral Research, Epidemiology, Surveillance, and Program Evaluation Team, Program Development Branch, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. qam2@cdc.gov
Preventing Chronic Disease
|December 17, 2005
Summary
Progress in diabetes preventive care varied between 2000 and 2003. While foot and A1c testing rates improved, eye exam rates declined, with some jurisdictions meeting Healthy People 2010 targets.
Area of Science:
- Public Health
- Preventive Medicine
- Diabetes Management
Background:
- The Centers for Disease Control and Prevention's National Diabetes Prevention and Control Program adopted Healthy People 2010 objectives in 1999.
- These objectives focus on improving preventive care for individuals with diabetes, including annual foot and eye exams and hemoglobin A1c tests.
Purpose of the Study:
- To evaluate progress towards meeting three specific Healthy People 2010 diabetes objectives.
- To assess changes in preventive care service rates between 2000 and 2003 and compare them to 2010 targets.
Main Methods:
- Utilized data from the Behavioral Risk Factor Surveillance System (BRFSS) diabetes module.
- Analyzed age-adjusted rates for foot examinations, hemoglobin A1c tests, and dilated eye examinations in 44-47 jurisdictions from 2000-2003.
Main Results:
- Annual foot examination rates increased from 63.7% to 69.3% (P < .001).
- Hemoglobin A1c test rates slightly increased from 68.3% to 69.5% (P = .35).
- Annual dilated eye examination rates decreased from 67.7% to 65.2% (P = .05).
Conclusions:
- The National Diabetes Prevention and Control Program should consider additional Healthy People 2010 objectives.
- Baseline rates and program data should be integrated for effective objective selection and progress evaluation.
- Linking program data with sources like BRFSS is crucial for understanding environmental factors and evaluating progress.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.